Evidence map›Paper›PMID 29327114›Full record

ArticleCancer causes & control : CCC2018

Anthropometric characteristics and ovarian cancer risk and survival.

Albina N Minlikeeva, Kirsten B Moysich, Paul C Mayor, John L Etter, Rikki A Cannioto, Roberta B Ness, Kristen Starbuck, Robert P Edwards, Brahm H Segal, Sashikant Lele and 3 more

Open access · greenAbstract read
In one paragraph

Article in Cancer causes & control : CCC, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Prevention of Epithelial Ovarian Cancer.Cold Spring Harbor perspectives in medicine · 2023
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Albina N MinlikeevaDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, A-352 Carlton House, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
Kirsten B MoysichDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, A-352 Carlton House, Elm and Carlton Streets, Buffalo, NY, 14263, USA. kirsten.moysich@roswellpark.org.
Paul C MayorDepartment of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.
John L EtterDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, A-352 Carlton House, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
Rikki A CanniotoDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, A-352 Carlton House, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
Roberta B NessThe University of Texas School of Public Health, Houston, TX, USA.
Kristen StarbuckDepartment of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Robert P EdwardsOvarian Cancer Center of Excellence, Womens Cancer Research Program, Magee-Womens Research Institute, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
Brahm H SegalDepartment of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Sashikant LeleDepartment of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Kunle OdunsiDepartment of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Brenda DiergaardeDepartment of Human Genetics, University of Pittsburgh Graduate School of Public Health, and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
Francesmary ModugnoOvarian Cancer Center of Excellence, Womens Cancer Research Program, Magee-Womens Research Institute, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
Roswell Park Comprehensive Cancer Center · USUPMC Hillman Cancer Center · USThe University of Texas Health Science Center at Houston · US

Funding

RPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2013 to 2025
$19.6M
Novel immunological biomarkers ovarian cancer prognosisR01CA188900 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B., SEGAL, BRAHM H. · 2015 to 2019
$3.3M
Regulatory T Cell Function in Ovarian CancerR01CA126841 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2009 to 2013
$3.0M
Postdoctoral Research Training in Surgical OncologyT32CA108456 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI YENDAMURI, SAIKRISHNA · 2006 to 2020
$2.8M
Inflammation and Ovarian CancerR01CA095023 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BUNKER, CLAREANN H. · 2003 to 2008
$2.7M
Interdisciplinary Training in Cancer Epidemiology at UBR25CA113951 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI FREUDENHEIM, JO L., MOYSICH, KIRSTEN B. · 2007 to 2016
$2.5M
NCI NIH HHS P50 CA159981NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA126841NCI NIH HHS R01 CA188900NCI NIH HHS R25 CA113951NCI NIH HHS T32 CA108456
6 · The paper itself

Abstract

purposeMultiple studies have examined the role of anthropometric characteristics in ovarian cancer risk and survival; however, their results have been conflicting. We investigated the associations between weight change, height and height change and risk and outcome of ovarian cancer using data from a large population-based case-control study.

methodsData from 699 ovarian cancer cases and 1,802 controls who participated in the HOPE study were included. We used unconditional logistic regression adjusted for age, race, number of pregnancies, use of oral contraceptives, and family history of breast or ovarian cancer to examine the associations between self-reported height and weight and height change with ovarian cancer risk. Cox proportional hazards regression models adjusted for age and stage were used to examine the association between the exposure variables and overall and progression-free survival among ovarian cancer cases.

resultsWe observed an increased risk of ovarian cancer mortality and progression for gaining more than 20 pounds between ages 18-30, HR 1.36; 95% CI 1.05-1.76, and HR 1.31; 95% CI 1.04-1.66, respectively. Losing weight and gaining it back multiple times was inversely associated with both ovarian cancer risk, OR 0.78; 95% CI 0.63-0.97 for 1-4 times and OR 0.73; 95% CI 0.54-0.99 for 5-9 times, and mortality, HR 0.63; 95% CI 0.40-0.99 for 10-14 times. Finally, being taller during adolescence and adulthood was associated with increased risk of mortality. Taller stature and weight gain over lifetime were not related to ovarian cancer risk.

conclusionsOur results suggest that height and weight and their change over time may influence ovarian cancer risk and survival. These findings suggest that biological mechanisms underlying these associations may be hormone driven and may play an important role in relation to ovarian carcinogenesis and tumor progression.

Indexed as

AnthropometryAdultAgedBody Mass IndexBody WeightCase-Control StudiesFemaleHumansMiddle AgedOvarian NeoplasmsRisk FactorsWeight GainHeightHeight changeOvarian cancer riskOvarian cancer survivalWeight

Identifiers

PMID29327114
PMCPMC5796836
OpenAlexW2783721430

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.